These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32884346)

  • 1. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
    Chau V; Bilusic M
    Cancer Manag Res; 2020; 12():7321-7330. PubMed ID: 32884346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
    Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
    Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
    Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
    Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for metastatic renal cell carcinoma.
    Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective.
    Yoo M; Nelson RE; Cutshall Z; Dougherty M; Kohli M
    JCO Oncol Pract; 2023 Mar; 19(3):e449-e456. PubMed ID: 36599117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
    Spisarová M; Melichar B; Vitásková D; Študentová H
    Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Miura N; Karakiewicz PI; Luzzago S; Schmidinger M; Bruchbacher A; Pradere B; Egawa S; Shariat SF
    Cancer Immunol Immunother; 2021 Feb; 70(2):265-273. PubMed ID: 32757054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
    Wang J; Li X; Wu X; Wang Z; Zhang C; Cao G; Zhang X; Peng F; Yan T
    EBioMedicine; 2019 Sep; 47():78-88. PubMed ID: 31439476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real world treatment sequences and outcomes for metastatic renal cell carcinoma.
    Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
    PLoS One; 2023; 18(11):e0294039. PubMed ID: 37992086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
    McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
    Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
    Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
    J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
    Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
    BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma.
    Ivanyi P; Wiegmann JP; Eggers H; Grünwald V
    Adv Ther; 2023 Sep; 40(9):3610-3619. PubMed ID: 37434067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
    Spisarová M; Melichar B; Vitásková D; Študentová H
    Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
    Santoni M; Rizzo A; Mollica V; Rosellini M; Marchetti A; Fragomeno B; Battelli N; Massari F
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):45-51. PubMed ID: 34058953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.